About Sironax
Sironax develops therapies for neurodegenerative, inflammatory, immunologic, metabolic, and rare diseases. It conducts clinical studies of SIR2501, SIR4156, and SIR9900. Sironax also develops the Brain Delivery Module platform. Its customers are patients with these diseases.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-B+
Global Headquarters
Waltham, United States
Team Size
51-100
Tracked Since
Oct 1, 2026
Web & Domain Identity
Official Website
sironax.com
Domain Registered Date
Jun 5, 2017
Social & Network Presence
LinkedIn Corporate
Not linked
Company Milestones & Timeline
- Capital Raise
Series-B+ announced
fundraisingfox.com
- Milestone
X account created (@Sironax_Ltd)
0 followers
- Capital Raise
Raised $200,000,000 · Series-B+
fundraisingfox.com
- Milestone
Website domain registered
sironax.com
Investors & Backers
Investor firms and individual backers were not publicly disclosed in available round filings for Sironax.
Funding History
Series-B+
· Sep 4, 2025
Undisclosed fundraisingfox.com
Series-B+
· Aug 2, 2022
$200,000,000 fundraisingfox.com
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026